Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Kalvista Pharmaceuticals Inc (KALV)

Kalvista Pharmaceuticals Inc (KALV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Kalvista Pharmaceuticals Inc 55 CAMBRIDGE PARKWAY SUITE 901E CAMBRIDGE MA 02142 USA

www.kalvista.com Employees: 150 P: 857-999-0075 F: 866-553-3269

Description:

KalVista Pharmaceuticals, Inc. is a pharmaceuticals company. It engages in discovery, development and commercialization of small molecule protease inhibitors for diseases with significant unmet need. Its product portfolio consist hereditary angioedema and diabetic macular edema, KVD818 and KVD001, which are in clinical stage. KalVista Pharmaceuticals, Inc., formerly known as Carbylan Therapeutics, Inc., is headquartered in Cambridge, United States.

Key Statistics

Overview:

Market Capitalization, $K 413,134
Enterprise Value, $K 381,344
Shares Outstanding, K 49,418
Annual Sales, $ 0 K
Annual Net Income, $ -126,640 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -42,270 K
EBIT, $ -171,640 K
EBITDA, $ -170,730 K
60-Month Beta 0.85
% of Insider Shareholders 10.50%
% of Institutional Shareholders 0.00%
Float, K 44,229
% Float 89.50%
Short Volume Ratio 0.57

Growth:

1-Year Return -24.00%
3-Year Return -42.11%
5-Year Return -48.99%
5-Year Revenue Growth -100.00%
5-Year Earnings Growth -149.28%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.91 on 12/05/24
Next Earnings Date N/A
Earnings Per Share ttm -3.64
EPS Growth vs. Prev Qtr -4.60%
EPS Growth vs. Prev Year -13.75%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-14 on 11/22/16

KALV Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -103.92%
Return-on-Assets % -88.06%
Profit Margin % 0.00%
Debt/Equity 0.00
Price/Sales N/A
Price/Cash Flow N/A
Price/Book 2.61
Book Value/Share 3.10
Interest Coverage -1.33
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar